A conversation with a senior ER director ignites a deeper debate at the heart of modern medicine — and reveals why the future of patient care may depend on physicians willing to hold two opposing truths at once.

In this article:

• The Upstream Advantage: Why the conflict between conventional and cellular medicine exists — and why both sides are right.
• The SS-31 Paradox: How FDA approval can create barriers for mitochondrial health.
• The WHI Lesson: How flawed science left millions of women without protection.
• The Academic Foundation: Building a formal infrastructure for cellular medicine.
• The Clinical Mandate: What responsible, physician-guided cellular medicine looks like at Newman MD LifeCare.

When a Conversation Gets Uncomfortable

It was supposed to be a Christmas party. End of shift. Noise. Laughter. The kind of environment where medicine usually fades into the background.

It didn’t.

Somewhere between introductions and small talk, I found myself in conversation with one of our senior directors — a physician responsible for overseeing multiple emergency departments. Experienced, thoughtful, and not easily persuaded by anything outside established medical systems.

We started where physicians usually do: shared cases, department challenges, the rhythm of emergency medicine. Then the tone shifted.

“I’m skeptical of where medicine is heading outside the traditional system,” he said. No edge. No hesitation. Just a clear, grounded statement. He was questioning the rise of functional and cellular-based private practice.

I didn’t argue with him. In over thirty years of practicing medicine — first on the front lines of emergency care, now at my practice, Newman MD LifeCare — I’ve learned that the most important conversations are often the uncomfortable ones.

The Upstream Advantage: Living in Two Worlds

I understood his perspective completely because I actively practice in both worlds simultaneously, nearly every single week.

In the emergency department, I practice traditional insurance-based conventional medicine regulated under strict protocol and FDA-approved medications. This is known as Downstream Medicine — where acute medical crisis presents itself. The system works. It saves lives. But it has limitations.

Once the acute crisis resolves, many patients enter a space where symptoms persist, but effective interventions disappear.

This is where cellular-based medicine enters the conversation. At Newman MD LifeCare, I practice direct-pay cellular medicine. Here, I focus on Upstream Medicine, utilizing therapies drawn from peer-reviewed literature — therapies that often exist outside conventional treatment not because they lack scientific merit, but because no pharmaceutical company has sponsored them through the multi-billion dollar FDA approval process.

This isn’t a compromise. It’s a unique advantage. Because I live in both worlds, I know when a patient needs conventional medicine, cellular approaches, or a blend of both. The same diagnostic rigor I apply in the ER — the same urgency about getting it right — travels with me into every cellular medicine consultation at my private clinic.

The Structural Constraint Few Talk About

The FDA approval process protects patients. Full stop. It has saved countless lives by preventing dangerous therapies from reaching the public.

But it is also shaped by economics, patents, and funding realities that have nothing to do with whether a therapy works. Natural compounds that can’t be patented, or repurposed generic peptides, often show remarkable promise in peer-reviewed research but remain outside the system because no company has discovered a profitable way to sponsor them.

The peptide SS-31 (Elamipretide) illustrates this perfectly. I have used this mitochondrial peptide successfully off-label for neurodegenerative conditions for years. When it recently received FDA approval for Barth syndrome — a meaningful milestone — the regulatory landscape suddenly shifted. Now that it carries a specific approved indication, access for patients with different mitochondrial conditions has become more complicated, not less.

Approval doesn’t always open doors. Sometimes it narrows them.

When the FDA Gets It Wrong: The WHI Study, a Cautionary Tale

The FDA’s handling of hormone therapy following the Women’s Health Initiative study is one of medicine’s clearest cautionary tales. In 2002, sweeping Black Box warnings were placed on all estrogen products — based on a study that tested synthetic hormones on older populations and made no distinction between those and natural Bioidentical Hormone Replacement Therapy.

Because of this misinterpretation, millions of women were denied therapy that could have protected their brains and bones for over two decades. It wasn’t until late 2025 that HHS Secretary RFK Jr. and FDA Commissioner Dr. Makary removed the Black Box warnings, acknowledging that the original guidance was shaped by bureaucratic inertia — and the warnings were updated to reflect the actual safety profile of the bioidentical hormones used in the study.

For more than two decades, women paid the price.

Building the Academic Foundation

“It’s all about the cell — and ultimately everything in medicine will be about the cell.” — Dr. William Seeds, SSRP

Medicine is moving toward a cellular-level understanding of disease, yet scientific progress is outpacing the training systems built to support it. This gap is why there are active Education Initiatives to build a formal academic foundation for cellular medicine.

In collaboration with medical schools and institutions like the SSRP, there is movement to create:

Structured Education — Moving beyond weekend seminars to deep, semester-based curriculum.

Rigorous Clinical Standards — Standardizing protocols for mitochondrial and peptide therapies.

Academic Validation — Ensuring that as we move upstream, we do so with the same peer-reviewed scrutiny expected of any other medical specialty.

Rigor and innovation are not opposing forces. They are a unified path toward deeper medical understanding and better patient care.

The Intelligent Cell Doctrine

At Newman MD LifeCare, we operate under a single conviction: the cell is amazingly intelligent and an expert survivalist. Our role as physicians is to give it what it needs to restore its own efficiency — no more, no less. This is what we call the Intelligent Cell Doctrine.

Aggressive attempts to manipulate cellular pathways without proper medical oversight can be catastrophic. This is precisely why my colleague’s skepticism is not only valid — it’s necessary. Innovation without structure is dangerous. But structure without flexibility can leave patients behind.

What Responsible Cellular Medicine Looks Like

Not all direct-pay cellular medicine practices are equal. And patients deserve to know the difference.

Every patient receives comprehensive medical evaluation. The same diagnostic rigor I apply in the emergency department travels with me into every cellular medicine consultation. I don’t guess at cellular dysfunction — I measure it.

Every protocol is grounded in peer-reviewed literature. I’m not limited to therapies pharmaceutical companies choose to sponsor. I access the full spectrum of published medical science and apply it with the same critical appraisal I would in any clinical setting.

Every intervention is monitored with hospital-level oversight. We track outcomes, watch for contraindications, and maintain safety standards built from decades of emergency medicine training. Careful evaluation, evidence-based decision-making, continuous monitoring, and clinical restraint — these aren’t optional extras. They are the foundation.

Compassionate use filings when warranted. For investigational treatments, I navigate the FDA’s own pathways for Compassionate Use access.

Knowing when cellular medicine isn’t the complete answer. When conventional treatment is needed, I know so. When both approaches work together, I coordinate them. That judgment — knowing which system serves the patient in front of you — is what separates physician-guided cellular medicine from a conventional practitioner.

Where Medicine Is Heading

The art of medicine lies in critical thinking — asking better questions and looking beyond surface explanations. Yet industrialized medicine has weakened that approach in many areas of healthcare.

Conventional and cellular-based medicine address different problems. One is built for acute crisis care; the other focuses on early dysfunction, restoration, and optimization before decline becomes irreversible. Both matter, but they require different tools and oversight.

Traditional physicians are right to be cautious. The FDA has saved countless lives by preventing unsafe interventions. At the same time, patients who have exhausted conventional options still deserve medically rigorous pathways that do not force a choice between safety and hope.

In practice, this distinction is clear. At Newman MD LifeCare, patients are evaluated through both lenses — acute diagnostic precision and cellular-level clinical insight.

Innovation without structure is dangerous. Structure without flexibility leaves patients behind. Progress in medicine happens between the two, one patient at a time.

Did you know?

The average FDA approval process takes 15 years and costs upward of $2.6 billion. While that rigor protects public health, it creates a significant structural barrier for natural compounds and repurposed peptides that aren’t patentable — leaving scientifically sound therapies in bureaucratic inertia for decades.

References:

1. Duncan, D. I. (2023). Reduction of Sarcopenia Using HIFEM and RF. American Journal of Biomedical Science & Research, 18(3).
2. Duncan, D., Kent, D. E., & Appelbaum, E. (2023). Quality of Life and Core Muscle Strength in Elderly Patients. Journal of Geriatric Medicine and Gerontology, 9, 151.
3. Goldstein, A. C., et al. (2024). Expanded-access use of elamipretide in a critically ill patient with Barth syndrome. Genetics in Medicine Open, 2, 101859.
4. Malkin, C. J., et al. (2004). The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men. The Journal of Clinical Endocrinology & Metabolism, 89(7), 3313–3318.
5. Mawatari, S., et al. (2020). Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids. Parkinson’s Disease, 2020, 1–7.
6. Rouzier, N. (2012). How to Achieve Healthy Aging (2nd ed.). Worldlink Medical Publishing.
7. Seeds, W. (2020). Peptide Protocols (Vol. 1). SSRP Institute.
8. U.S. Food and Drug Administration. (2017). Expanded Access to Investigational Drugs for Treatment Use. U.S. Department of Health and Human Services.
9. Walker, S. (2019). Expanded Access Versus Right-to-Try. Hospital Pharmacy, 55(2), 79–81.

To learn more about our physician-guided approach to cellular medicine, visit newmanlifecare.com or schedule a private consultation at our Chatsworth estate.